Parkman Healthcare Partners LLC Takes Position in Carlsmed, Inc. $CARL

Parkman Healthcare Partners LLC acquired a new stake in Carlsmed, Inc. (NASDAQ:CARL) in the second quarter, according to the company in its most recent filing with the SEC. The firm acquired 597,318 shares of the company’s stock, valued at approximately $6,200,000.

A number of other institutional investors have also recently added to or reduced their stakes in CARL. KCM Capital Inc acquired a new position in Carlsmed in the 1st quarter valued at approximately $1,810,000. Janus Henderson Group PLC lifted its holdings in shares of Carlsmed by 7.6% during the first quarter. Janus Henderson Group PLC now owns 1,227,452 shares of the company’s stock worth $11,108,000 after purchasing an additional 86,834 shares during the period. Sectoral Asset Management Inc. acquired a new position in shares of Carlsmed during the fourth quarter worth $589,000. Wesbanco Bank Inc. bought a new stake in shares of Carlsmed in the fourth quarter worth $457,000. Finally, Wells Fargo & Company MN grew its stake in shares of Carlsmed by 61.7% in the fourth quarter. Wells Fargo & Company MN now owns 7,834 shares of the company’s stock worth $97,000 after purchasing an additional 2,989 shares during the last quarter.

Analyst Ratings Changes

Several research analysts recently issued reports on the company. Needham & Company LLC started coverage on Carlsmed in a research report on Wednesday, July 1st. They set a “buy” rating and a $17.00 target price for the company. Truist Financial upped their price target on Carlsmed from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Thursday, August 6th. Wall Street Zen raised Carlsmed from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Weiss Ratings raised Carlsmed from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Finally, BTIG Research reiterated a “buy” rating and issued a $23.00 target price on shares of Carlsmed in a report on Wednesday, May 6th. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $19.25.

Carlsmed Price Performance

CARL stock opened at $15.80 on Tuesday. The firm has a market cap of $431.39 million and a price-to-earnings ratio of -11.05. The company has a quick ratio of 8.66, a current ratio of 8.84 and a debt-to-equity ratio of 0.18. Carlsmed, Inc. has a 12-month low of $8.50 and a 12-month high of $17.23. The company’s fifty day simple moving average is $12.33 and its 200 day simple moving average is $11.47.

Carlsmed (NASDAQ:CARL) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.39) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.01. Carlsmed had a negative return on equity of 38.06% and a negative net margin of 57.42%.The firm had revenue of $18.94 million during the quarter. On average, analysts expect that Carlsmed, Inc. will post -1.5 earnings per share for the current year.

About Carlsmed

We are a commercial-stage medical technology company pioneering AI-enabled personalized spine surgery solutions with a mission to improve outcomes and decrease the cost of healthcare for spine surgery and beyond. We are focused on becoming the standard of care for spine fusion surgery. The aprevo Technology Platform consists of artificial intelligence (“AI”)-enabled software solutions, and interbody implants that we custom design for each patient’s unique pathology and vertebral bone topography, and single-use surgical instruments (the “aprevo Technology Platform”).